106
Participants
Start Date
November 30, 2007
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
IMC-1121B (ramucirumab)
10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
Dacarbazine
1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
ImClone Investigational Site, New York
ImClone Investigational Site, New York
ImClone Investigational Site, Buffalo
ImClone Investigational Site, Willow Grove
ImClone Investigational Site, Jacksonville
ImClone Investigational Site, Orlando
ImClone Investigational Site, Decatur
ImClone Investigational Site, Oxford
ImClone Investigational Site, Missoula
ImClone Investigational Site, Dallas
ImClone Investigational Site, Houston
ImClone Investigational Site, Aurora
ImClone Investigational Site, Scottsdale
ImClone Investigational Site, Scottsdale
ImClone Investigational Site, Fresno
ImClone Investigational Site, San Francisco
ImClone Investigational Site, Seattle
Eli Lilly and Company
INDUSTRY